Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
The Davenport Value & Income Fund George L. Smith III, Michael S. Beall, Adam Bergman | “International Flavors & Fragrances Inc. (IFF) manufactures and sells key ingredients to Consumer Products companies – think of laundry detergent scents and food textures and flavors. The company is divesting non-core businesses, including the most-recent announcement that it will sell its Food Ingredients segment for $4.3 billion. IFF indicates it will steer divestiture proceeds to share buyback and debt paydown. Meanwhile, the company's remaining (core) businesses are likely to show a faster growth and higher margin profile, which we believe ultimately ought to translate into a higher valuation. Similar to Abbott, IFF traded near 16x earnings at the time of our purchase, below long-term averages, with shares sporting a 2% dividend yield.” | NEUTRAL | Q2 2026 Jul 28, 2026 | View Pitch |
The Davenport Core Leaders Fund George L. Smith III, Jeffrey Omohundro, Christopher G. Pearson | “The company's asset divestitures are clearing a path for a higher-margin, faster-growing core business. Proceeds from these non-core sales are set to fund debt reduction and share repurchases, providing a clear path to valuation re-rating. Additionally, the stock represents an entry point at a below-average valuation of 16x earnings.” | BULL | Q2 2026 Jul 28, 2026 | View Pitch |
Heartland Mid Cap Value Fund Colin McWey, Will Nasgovitz, Troy McGlone | “A new deep-value holding is International Flavors and Fragrances (IFF), a specialty ingredient producer that sells flavors, fragrances, and enzymes to food, beverage, personal care, household products, and human health product manufacturers. This is an example of identifying a self-help opportunity through bottom-up research. For more than two years, management has worked on streamlining IFF's portfolio and operations to focus on higher-margin businesses where it enjoys leading market share, better pricing power, attractive growth, and significantly enhanced capital allocation flexibility. This strategy follows years of wayward capital allocation executed by prior management. Today, IFF's revenue is evenly split across three segments. Taste accounts for 30% of profits, Health & Biosciences generates 37%, and Scent contributes 32%. In the Scent segment, IFF's pioneering of encapsulated fragrance technology secured its leadership in fabric care, a position now expanding into scent boosters, shampoos, and body washes. Driven by improving growth, margins, and free cash flow, we believe IFF is poised to operationally resemble industry leader Givaudan. Yet while Givaudan trades at 19.14X forward EBITDA, IFF trades at a steep discount of just 12.23X. Highlighting management's confidence in this valuation gap closing, the company recently instituted its first share buyback program in six years.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
FPA Source Capital Source Capital Portfolio Managers | “Poor management has plagued International Flavors & Fragrances for years. As a leading producer of food, beverage, scent, home and personal care, and health products and ingredients, its products are ubiquitous across many household staples. They produce one -third of probiotics, the enzyme used in half of cold -water laundry detergents, another enzyme used in 20% of the beer brewed globally, and one -third of yogurts use an IFF culture, to name a few. Prior management's reckless capital allocation and ineptit ude at managing its diverse global enterprise, transforming a high -margin, unlevered company into one with a lower margin and a higher level of leverage. We have a constructive view of the new CEO, who has renewed the company's focus on being a best -in -cla ss operationally with a smaller product suite. They have sold, and will continue to sell, non -core assets, which will decrease their leverage and, hopefully, allow for higher margins. The company has burned the market, and many investors have taken a wait -and -see attitude reasonably. We believe that their current $4 of free cash earnings could increase to $5 -6 in a few years, and if successful, their P/E should also rise. With its stock currently at $67, a reasonable downside could be around $60, and its upside could be around $125 (a three -year view that excludes free cash flow). BSD Analysis: International Flavors & Fragrances is successfully executing its Project Revival turnaround, focusing on high-margin core segments like Scent and Taste to drive volume-led growth in 2026. The company recently surpassed Q4 revenue expectations, with a significantly improved debt-to-EBITDA ratio signaling a healthier balance sheet. While earnings per share have seen some near-term pressure from restructuring costs, multiple analyst upgrades highlight a positive outlook for margin expansion as operational efficiencies take hold. Management's 2026 sales guidance of up to 10.8 billion dollars reflects a cautious but steady recovery in global consumer demand. With strategic divestitures of non-core assets nearly complete, IFF is well-positioned to leverage its R&D leadership to capture emerging opportunities in the health and biosciences markets.” | BULL | Q4 2025 Feb 10, 2026 | View Pitch |
FPA Source Capital Source Capital Portfolio Managers | “ICON is a high-quality Contract Research Organization (CRO) that has achieved unprecedented scale and efficiency, making it the definitive platform for outsourced drug development. The entire investment thesis is underpinned by the $12 billion acquisition of PRA Health Sciences, which eliminated a key competitor and created a dominant, top-tier CRO with over $8 billion in trailing revenue. The current stock dislocation, despite strong Adjusted EBITDA growth (up 8.7% in Q2 2024) and robust free cash flow (FCF) generation ($687 million YTD), is an overreaction to slower biotech funding and temporary elevated cancellation rates. The fundamental value proposition is protected by: Massive Backlog: A formidable, highly visible $24.7 billion backlog that secures revenue for years to come. Technological Moat: Aggressive investment in AI-enabled trial solutions (iSubmit, FORWARD+) and the market-critical shift to decentralized and hybrid trials (inherited from PRA) which fundamentally reduce the cost and time of drug development for sponsors. Capital Return: Disciplined capital allocation focused on deleveraging the balance sheet and executing a substantial $750 million share repurchase program year-to-date. Trading at a modest 18x-25x forward earnings (a discount to its historical premium), ICON is a clear-cut case where operational strength and scale are poised to force a major re-rating once the market moves past the temporary industry headwinds. BSD Analysis: IFF is a classic specialty-chemicals turnaround with strong underlying franchises but a damaged balance sheet and credibility problem after years of undisciplined M&A. The new leadership team is prioritizing divestitures, cost reductions, and simplification, which should gradually lift margins and free cash flow while pulling leverage down to more comfortable levels. At today's valuation, the stock trades at a discount to its historical multiples and to higher-quality peers, implicitly assuming only modest improvement in profitability. If management can deliver mid-single-digit sales growth with a return to more typical specialty-chem margins, equity holders could see both earnings growth and multiple expansion. The key catalysts are asset sales, visible debt reduction, and evidence of sustained margin progress over several quarters. Risks include execution challenges in a complex global footprint, potential price pressure from large consumer-product customers, and any re-acceleration of input cost inflation.” | BULL | Q3 2025 Nov 7, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
